Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 233M 217M | Sales 2025 * | 252M 235M | Capitalization | 377M 351M |
---|---|---|---|---|---|
Net income 2024 * | -50M -46.58M | Net income 2025 * | -29M -27.02M | EV / Sales 2024 * | 0.28 x |
Net cash position 2024 * | 313M 291M | Net cash position 2025 * | 315M 293M | EV / Sales 2025 * | 0.25 x |
P/E ratio 2024 * |
-7.34
x | P/E ratio 2025 * |
-12.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.73% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | Nov. 14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock